Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT01932450
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Mei changlin
- Registry
-
NCT01932450
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01932450. Randomized; no masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
- Acronym
- RAFALE
- Condition
- Autosomal Dominant Polycystic Kidney Disease
- Condition
- Hypertension
- Intervention (Procedure)
- renal sympathetic denervation
- Intervention (Drug)
- antihypertensive drugs
- Lead sponsor
- Mei changlin
Record details
- Record id
cardio:ct-nct01932450- Content hash
a682af10494bd27c167805ed904c701986f05b4f3792177ee79659b471e79e3c